LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Verve Therapeutics Inc

Aperta

11.28 0.71

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.2

Massimo

11.28

Metriche Chiave

By Trading Economics

Entrata

19M

-31M

Vendite

20M

33M

EPS

-0.35

Margine di Profitto

-94.108

Dipendenti

274

EBITDA

19M

-35M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+34.34% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

604M

992M

Apertura precedente

10.57

Chiusura precedente

11.28

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Verve Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 giu 2025, 11:56 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

17 giu 2025, 14:02 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 giu 2025, 12:12 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 giu 2025, 11:01 UTC

Acquisizioni, Fusioni, Takeovers

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 giu 2025, 10:47 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 giu 2025, 10:47 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 giu 2025, 10:46 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 giu 2025, 10:45 UTC

Acquisizioni, Fusioni, Takeovers

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 giu 2025, 09:33 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Verve Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

34.34% in crescita

Previsioni per 12 mesi

Media 15.06 USD  34.34%

Alto 24 USD

Basso 11 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Verve Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

4

Acquista

6

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.1501 / 5.16Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.